Coloplast Takes Strategic Steps in Business Simplification
Coloplast has decided to divest its core Skin Care product portfolio as part of a broader strategy to optimize its operations and enhance its profitability in the Advanced Wound Care segment.
In the fiscal year 2023/24, the revenue generated from the Skin Care products reached approximately DKK 400 million. Notably, the operating profit from this segment was considerably below the group's average EBIT margin, prompting the company to pursue this strategic divestment.
Financial Guidance Remains Steady
Despite the divestment, Coloplast has maintained its financial outlook for fiscal year 2024/25. The company anticipates organic revenue growth of 8-9%, alongside an EBIT margin before special items projected at around 28%. These expectations already factor in the impact of the divestment, demonstrating the company's commitment to maintaining a robust financial foundation as it realigns its portfolio.
This portfolio simplification is expected to positively influence the operating profitability of the Advanced Wound Care business. It is estimated that this move will contribute substantially to the group EBIT margin, with around 30 basis points of positive impact noted in the recent fiscal disclosures.
Revenue Impact and One-Off Items
The divestment will result in a reduction of around DKK 350 million in reported revenue for FY 2024/25, reflecting a negative impact of approximately -1.5 percentage points on overall revenue growth. However, the company has integrated one-off items related to this divestment into its fiscal expectations, which amount to DKK 130 million.
The completed transaction, which was finalized in early December, marks a significant realignment for Coloplast, although specific details related to the transaction have not been publicly disclosed.
Contacts for Investors and Media
Investors and Analysts
For inquiries, Anders Lonning-Skovgaard, Executive Vice President and CFO, can be reached at +45 4911 1111. Additionally, Aleksandra Dimovska, Vice President of Investor Relations, is available at +45 4911 2458.
Media Relations:
Peter Mønster, Senior Media Relations Manager, can be contacted at +45 4911 2623.
Frequently Asked Questions
What prompted the divestment of the Skin Care portfolio by Coloplast?
The divestment is part of Coloplast's strategy to simplify operations and enhance profitability within its Advanced Wound Care business.
How does the divestment impact Coloplast's financial guidance?
Coloplast's financial guidance for FY 2024/25 remains unchanged, with projected organic revenue growth of 8-9% and EBIT margins around 28%, which includes the effects of the divestment.
What is the expected revenue decline from the divestment?
The divestment is expected to reduce reported revenue by approximately DKK 350 million and negatively affect revenue growth by about -1.5 percentage points.
What are the financial implications of the one-off items?
One-off items related to the divestment are included in the company's expectations for special items, totaling around DKK 130 million.
Who can be contacted for more information on this strategic move?
Interested parties may reach out to Anders Lonning-Skovgaard or Aleksandra Dimovska for investor-related queries, or Peter Mønster for media inquiries.
